Grant to Support Drug for Hearing Loss Treatment- April 2016- The ASHA Leader
A $2.06 million NIH Phase 2 grant was given to Oricula Therapeutics, LLC to help support the development of a drug that can prevent hearing loss caused by aminoglycoside antibiotics. These anti-biotics are given to individuals who have serious infectious diseases, such as septicemia and tuberculosis and have been known to cause irreversible hearing loss or even deafness in 20% of this population.